Verismo Highlights Potential of Solid Tumor CAR-T Therapy at AACR Meeting

HLB Innovation’s subsidiary, Verismo, has received recognition for its solid tumor therapy 'SynKIR-110', which is being evaluated as a treatment that demonstrates the potential of CAR-T therapies for solid tumors.

On the 20th, Professor Janos Tanyi presented the interim results of the SynKIR-110 clinical phase 1 trial (STAR-101) at the plenary session of the American Association for Cancer Research (AACR 2026). HLB Innovation

The results of this study were presented on April 20 (local time) at the plenary session (CTPL), the highest authority session of the American Association for Cancer Research (AACR 2026). Janos Tanyi, Associate Professor at the Perelman School of Medicine, University of Pennsylvania, and Principal Investigator for the SynKIR-110 Phase 1 clinical trial, emphasized that, even at low doses, meaningful tumor shrinkage was observed in patients with advanced solid tumors expressing mesothelin, including ovarian cancer, mesothelioma, and cholangiocarcinoma, all of whom have limited treatment options. He also noted that the efficacy signals became more pronounced as the dosage increased.

Tumor responses were observed in 4 out of 9 evaluable patients, with a maximum tumor reduction of up to 47%. In cohort 3, one of the two patients maintained a partial response (PR) according to the immune Response Evaluation Criteria in Solid Tumors (iRECIST) for up to 6 months of follow-up. The Phase 1 dose escalation trial of SynKIR-110 demonstrated an overall favorable safety profile.

According to the presentation, no dose-limiting toxicities (DLTs) or protocol-defined adverse events leading to discontinuation were reported across cohorts 1 to 3. Cytokine release syndrome (CRS) occurred in 3 out of 9 patients, but all cases were grade 2 or lower, and no immune effector cell-associated neurotoxicity syndrome (ICANS) was observed.

Sandip Patel, Professor at UC San Diego School of Medicine, commented, "Given the concerns about on-target off-tumor toxicity in existing mesothelin CAR-T therapies, the SynKIR-110 study strategy to minimize this risk is meaningful."

Meanwhile, Verismo is currently continuing the Phase 1 clinical trial of SynKIR-110 in the United States, with dose escalation and patient enrollment ongoing to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose.

This content was produced with the assistance of AI translation services.